Big Pharma drops sharply ahead of Trump’s tariff announcement
Seeking Alpha News (Tue, 1-Apr 3:43 PM ET)
TipRanks (Tue, 1-Apr 8:15 AM ET)
Globe Newswire (Mon, 31-Mar 1:00 PM ET)
Piper Sandler Keeps Their Buy Rating on Teva Pharmaceutical (TEVA)
TipRanks (Mon, 31-Mar 6:56 AM ET)
Teva Releases Q1 2025 Aide Memoire
Globe Newswire (Thu, 27-Mar 4:30 PM ET)
Globe Newswire (Thu, 27-Mar 4:30 PM ET)
Globe Newswire (Mon, 3-Mar 4:30 PM ET)
Globe Newswire (Thu, 27-Feb 8:00 AM ET)
Globe Newswire (Tue, 25-Feb 4:00 PM ET)
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Teva Pharmaceutical Industries Limited American Depositary Shares trades on the NYSE stock market under the symbol TEVA.
As of April 1, 2025, TEVA stock price declined to $15.29 with 6,492,782 million shares trading.
TEVA has a beta of 0.54, meaning it tends to be less sensitive to market movements. TEVA has a correlation of 0.02 to the broad based SPY ETF.
TEVA has a market cap of $17.52 billion. This is considered a Large Cap stock.
Last quarter Teva Pharmaceutical Industries Limited American Depositary Shares reported $4 billion in Revenue and $.71 earnings per share. This beat revenue expectation by $109 million and exceeded earnings estimates by $.01.
In the last 3 years, TEVA traded as high as $22.80 and as low as $6.78.
The top ETF exchange traded funds that TEVA belongs to (by Net Assets): IEFA, EFA, EFV, PPH, IXUS.
TEVA has underperformed the market in the last year with a price return of +8.4% while the SPY ETF gained +8.6%. TEVA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -30.6% and -8.5%, respectively, while the SPY returned -4.0% and -0.8%, respectively.
TEVA support price is $14.98 and resistance is $15.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TEVA shares will trade within this expected range on the day.